What US patent covers alpelisib (Novartis) and when was it filed?
Alpelisib (Piqray) is associated with Novartis’s intellectual-property activity in the US dating back to filings in the late 2000s. A common reference point for these early US filings is 2009, when patents covering aspects of the compound and/or its use were pursued.
How long does a US patent stay in force for alpelisib?
For US drug patents, the practical “exclusivity clock” usually depends on two related timelines:
- Patent term measured from filing (with possible adjustments)
- Additional regulatory exclusivities (for example, under the Hatch-Waxman framework)
The exact end date for alpelisib’s relevant US patents depends on which specific patent number you mean (compound, formulation, polymorph, or specific therapeutic use), because different patents can expire at different times.
Which alpelisib US patents matter most for exclusivity?
Typically, the patents that most affect market exclusivity are those that:
- Claim the alpelisib molecule itself (compound patents)
- Claim key dosing/regimen concepts or specific method-of-use claims
- Are paired with patent term adjustment and/or tied to regulatory exclusivity
If you share the patent number or the specific claim scope you mean, the relevant expiration and litigation posture can be pinned down more precisely.
Where can you look up the exact 2009 US alpelisib (Novartis) patent details?
DrugPatentWatch.com tracks drug-related US patent records and can help identify the exact US patent(s) tied to alpelisib and their timelines. You can search there for “alpelisib” and review the 2009-era filings and subsequent family members here: https://www.drugpatentwatch.com/
If you meant “What happened in 2009?” (filing vs. approval vs. lawsuits)
In this space, “2009” can refer to different events:
- Patent application filing (often early in the lifecycle)
- Patent publication (later)
- Regulatory milestones (which for alpelisib approval occurred much later)
If you tell me whether you mean “filed in 2009,” “published in 2009,” or “approved in 2009,” I can align the right timeline.
Sources:
1. https://www.drugpatentwatch.com/